Trials / Completed
CompletedNCT05674344
Calibration and Validation of the Masimo Temperature Device in Febrile Patients
Calibration and Validation of the Masimo Rad-G With Temperature Device in Febrile Patients
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 170 (actual)
- Sponsor
- Masimo Corporation · Industry
- Sex
- All
- Age
- 1 Year
- Healthy volunteers
- Not accepted
Summary
The goal of this clinical trial is to test the performance of the Masimo noninvasive temperature device in patients with fever. The main question it aims to answer is whether the Masimo temperature device is comparable to standard methods of taking temperature such as inserting a probe under the tongue or using a forehead thermometer. Participants will be asked to sit still while rounds of measurements are taken using the Masimo temperature device and the reference temperature device. Researchers will compare the measurements taken with the Masimo device with the measurements taken with the reference device.
Detailed description
Individual sites are only representative of a subset of the overall population, per ISO 80601-2-56:2017(Medical electrical equipment - Part 2-56: Particular requirements for basic safety and essential performance of clinical thermometers for body temperature measurement), and therefore clinical bias and limits of agreement should not be evaluated for the subsets. Publication of results should include repeatability from individual sites and the combined clinical bias and limits of agreement (NCT05787782, NCT05674344, and NCT05779397)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Masimo Temperature device | Non-invasive temperature device |
Timeline
- Start date
- 2022-12-01
- Primary completion
- 2023-03-02
- Completion
- 2023-03-02
- First posted
- 2023-01-06
- Last updated
- 2023-07-25
- Results posted
- 2023-07-25
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT05674344. Inclusion in this directory is not an endorsement.